SELECTA BIOSCI. DL -,0001
SELECTA BIOSCI. DL -,0001
Action · US8162121045 · SELB · A2AML0 (LSSI)
Aperçu Indicateurs financiers
Pas de cours
n/a

Performance

Jour Semaine Mois 3 mois 6 mois 1 an 5 ans
- - - - -1,87 % 0,32 % -80,72 %

Profil de l'entreprise pour SELECTA BIOSCI. DL -,0001 Action

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

Fonds investis

Les fonds suivants ont investi dans : SELECTA BIOSCI. DL -,0001 investi :

Fonds
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. en millions
15,70
Part (%)
0,04 %

Données de l'entreprise

Nom SELECTA BIOSCI. DL -,0001
Société Selecta Biosciences, Inc.
Symbole SELB
Site web https://selectabio.com
Marché d'origine LSSI Lang & Schwarz
WKN A2AML0
ISIN US8162121045
Type de titre Action
Secteur Healthcare
Industrie Biotechnology
PDG Dr. Carsten Brunn Ph.D.
Capitalisation boursière 135 Mio
Pays États-Unis d'Amérique
Devise EUR
Employés 0,1 T
Adresse 65 Grove Street, 02472 Watertown
Date d'introduction en bourse 2016-06-22

Symboles boursiers

Nom Symbole
NASDAQ SELB

Autres actions

Les investisseurs qui détiennent SELECTA BIOSCI. DL -,0001 ont également les actions suivantes dans leur portefeuille :
AMGEN INC
AMGEN INC Action
ARAB REPUBLIC OF EGYPT (THE) 5.75% NTS 29/05/24 (144A)
ARAB REPUBLIC OF EGYPT (THE) 5.75% NTS 29/05/24 (144A) Obligation
AUTODESK INC
AUTODESK INC Action
CISCO SYSTEMS INC
CISCO SYSTEMS INC Action
COSTCO WHOLESALE CORP
COSTCO WHOLESALE CORP Action
ELECTRONIC ARTS INC
ELECTRONIC ARTS INC Action
GOCHAIN
GOCHAIN Crypto
INTEL CORP
INTEL CORP Action
JPMORGAN CHASE & CO
JPMORGAN CHASE & CO Action
MICROSOFT CORP
MICROSOFT CORP Action
NXP SEMICONDUCTORS NV
NXP SEMICONDUCTORS NV Action
PHARMING GRP SP. ADRS
PHARMING GRP SP. ADRS Certificat de dépôt
UPWORK INC
UPWORK INC Action
WALGREENS BOOTS ALLIANCE INC
WALGREENS BOOTS ALLIANCE INC Action
La plateforme financière MoneyPeak suit et analyse les investissements et les portefeuilles. Du dépôt de titres à l'achat de crypto.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.
Mentions légales Protection des données Blog Communauté Retour d'information Changelog
Im App Store herunterladen Bei Google Play herunterladen
Tous droits réservés © LCP GmbH 2025